Feed/Companies/Artios Pharma

Artios Pharma

As of 14 Oct 2026, Artios Pharma has raised $115M across 1 verified round on record; latest: $115 million Series D led by RA Capital Management and SV Health Investors, announced 17 Nov 2025.

BUILT ON

Visit site

Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options.

artios.comLinkedInBiotech

LATEST ROUND

Series D

$115M · 2025-11-17

RAISED ON RECORD · USD

$115M

across 1 verified round

INVESTORS

2 leads

SOURCES

from 1 publisher

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series D

$115M · 2025-11-17

[ HISTORY ]

led by RA Capital Management, SV Health Investors

Round	Amount	Announced	Lead	Buzz
Series D [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$115M	2025-11-17	RA Capital Management, SV Health Investors	No recent discussion
1 source [ VERIFIED ] read against 1 source Published by hand (biopharmadive.com): "Artios Pharma announced a $115 million Series D round on Nov. 17, 2025": hand-checked (K, non-US): the page states the company, the equity amount and the day

Artios Pharma

Company

Rounds

Sources

Profile

Investors

Artios Pharma

Rounds

Profile

Sources

Series D$115M2025-11-171 source

Investors

Series D$115M2025-11-175 investors